ABSTRACT Plasma of individuals recovered from COVID-19 is needed to address the immediate demand for treatment of SARS-CoV-2 infected patients in severe conditions This communication: highlights the need for COVID-19 convalescent plasma collections to manufacture hyperimmune immunoglobulin therapies, which take months to develop;advocates for the collection of convalescent plasma from asymptomatic donors who tested positive for SARS-CoV-2 virus but did not develop symptoms of the disease;and suggests to use convalescent plasma for transfusion as well as future hyperimmune immunoglobulins as pre- and post-exposure prophylactic treatments for individuals with high risks of exposure to the virus or contracting severe disease